{"id":"W4407285619","doi":"10.1093/jcag/gwae059.191","title":"A191 REAL WORLD USE OF ADALIMUMAB BIOSIMILAR AMGEVITA® (ABP-501) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN CANADA","year":2025,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Biosimilar; Adalimumab; Inflammatory bowel disease; Medicine; Inflammatory Bowel Diseases; Internal medicine; Disease; Gastroenterology; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005976727,0.0001239585,0.000442173,0.0005108882,0.00004123375,0.000005793656,0.0002866112,0.0001255413,0.00004356911],"category_scores_gemma":[0.0004178995,0.00009043047,0.000102439,0.0002729411,0.0001094974,0.00007487361,0.00004131303,0.000435558,2.242968e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002266087,"about_ca_system_score_gemma":0.002248963,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.5490739,"about_ca_topic_score_gemma":0.9984319,"domain_scores_codex":[0.997924,0.0007294055,0.0007617702,0.0001154907,0.0001091864,0.0003600981],"domain_scores_gemma":[0.9983826,0.000196811,0.0008829217,0.0001749867,0.0002818938,0.0000807715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001212163,0.00007215658,0.9934627,0.0000189571,0.0002040478,0.00000775632,0.00002132126,0.0001510311,0.00006790771,0.00005591465,0.004646721,0.0000793254],"study_design_scores_gemma":[0.002560218,0.0001755434,0.9953865,0.0001519951,0.0000813147,6.24209e-7,0.00002068461,0.000009224591,0.0001222487,0.00004464793,0.001400203,0.00004676791],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922721,0.0000340985,0.000002554019,0.006841265,0.0005025446,0.000146334,0.0001499145,9.059922e-7,0.00005024099],"genre_scores_gemma":[0.9980935,0.00001853402,0.0000777257,0.001477974,0.00000796004,0.000001451949,0.000005306344,0.000006017768,0.0003114813],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.449358,"threshold_uncertainty_score":0.5925738,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005826618595907135,"score_gpt":0.2047474966732414,"score_spread":0.1989208780773342,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}